Effect of enhanced iron chelation therapy on glucose metabolism in patients with β‐thalassaemia major
- 18 July 2006
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 134 (4), 438-444
- https://doi.org/10.1111/j.1365-2141.2006.06203.x
Abstract
Recently introduced chelation regimens that combine deferoxamine (DFO) and deferiprone have been shown to have greater efficacy in promoting iron excretion than either chelator alone and have been associated with rapid reduction of the iron load in the heart and liver, and with reversal of cardiac dysfunction. It is unclear whether this combined therapy could be associated with a reduction in iron load or decline in the severity of iron-induced endocrinopathies. Starting in January 2001, 42 patients with beta-thalassaemia major, previously maintained on subcutaneous DFO only, were switched to combined treatment with DFO and deferiprone. The primary endpoint was to investigate the effects of this therapy on the glucose metabolism characteristics of this population. Combination therapy markedly decreased ferritin levels (638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose responses were improved at all times during an oral glucose tolerance test, particularly in patients in early stages of glucose intolerance. Glucose quantitative secretion also decreased significantly with combined therapy, while no significant change occurred in insulin levels in any group. Insulin secretion, according to the homeostasis assessment model, markedly increased in all groups, while overall reduction in insulin sensitivity did not reach statistical significance. This study showed that the combination of DFO and deferiprone was associated with an improvement in liver iron deposition and glucose intolerance.Keywords
This publication has 32 references indexed in Scilit:
- Reduced insulin secretion in normoglycaemic patients with β‐thalassaemia majorDiabetic Medicine, 2006
- Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood, 2006
- Hypoparathyroidism in transfusion-dependent patients with β-thalassemiaJournal of Bone and Mineral Metabolism, 2006
- Evaluation of Bone Mineral Density of the Lumbar Spine in Patients With β-Thalassemia Major With Dual-Energy X-Ray Absorptiometry and Quantitative Computed TomographyJournal of Pediatric Hematology/Oncology, 2006
- Reversibility of hypogonadotropic hypogonadism in a patient with the juvenile form of hemochromatosisFertility and Sterility, 2005
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Role of deferiprone in chelation therapy for transfusional iron overloadBlood, 2003
- Multicentre study on prevalence of endocrine complications in thalassaemia majorClinical Endocrinology, 1995
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorThe New England Journal of Medicine, 1994
- Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by HypertransfusionThe New England Journal of Medicine, 1988